(Q85691037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Joel W Neal

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

George W Sledge

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

7 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

627-628

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Ceritinib in ALK-rearranged non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Trastuzumab emtansine for HER2-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.171

10.1038/NRCLINONC.2014.171

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25286974%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference